SEC Comment Letter 0000000000-24-009477 to Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc.
Date: Aug. 19, 2024 · CIK: 0001400118 · Accession: 0000000000-24-009477
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281582
Letter
August 19, 2024 Dave Happel Chief Executive Officer Sagimet Biosciences Inc. 155 Bovet Road, Suite 303 San Mateo, CA 94402 Re:Sagimet Biosciences Inc. Registration Statement on Form S-3 Filed August 15, 2024 File No. 333-281582 Dear Dave Happel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jennifer Porter
Show Raw Text
August 19, 2024
Dave Happel
Chief Executive Officer
Sagimet Biosciences Inc.
155 Bovet Road, Suite 303
San Mateo, CA 94402
Re:Sagimet Biosciences Inc.
Registration Statement on Form S-3
Filed August 15, 2024
File No. 333-281582
Dear Dave Happel:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jennifer Porter